# Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

> **NCT03976882** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 129 (actual)

## Conditions studied

- Chemotherapy-Induced Thrombocytopenia

## Interventions

- **DRUG:** Hetrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03976882
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976882, "Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03976882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*